Please login to the form below

Not currently logged in
Email:
Password:

South Africa to spend USD 688.2m on HIV drugs

The South African government's department of trade and industry (DTI) has announced it will spend about ZAR 5bn (USD 688.2m) on anti-retrovirals (ARVs) in the next three years to augment domestic production of the drugs.

The South African government's department of trade and industry (DTI) has announced it will spend about ZAR 5bn (USD 688.2m) on anti-retrovirals (ARVs) in the next three years to augment domestic production of the drugs.

According to the Medical Research Council, 5.4m people are living with HIV/Aids in South Africa, which is the second most infected population after India.

The DTI added that increased local production of ARVs would make it economically viable for pharmaceutical companies to manufacture them locally and reduce associated costs. At the moment, active pharmaceutical ingredients (APIs) for making ARVs are imported, pushing up running costs for manufacturing plants in the region.

Andrew Kudlinski, director for geographic projects at the DTI, said: "Manufacturing ARVs involves complex technology and is costly. A company must make large volumes to make it economically justifiable and if you have a three-year contract, the manufacturer can justify the investment.î

"South Africa has the capacity to manufacture most ARVs locally but 100 percent of the active pharmaceuticals ingredients are imported and we can use state procurement to encourage the domestic manufacturing of APIs in the future," added Kudlinski.

Nimrod Zalk, the DTI's chief director of industrial policy, explained that the government was concerned about the import ratio in the drugs sector, which was worth ZAR 17.7 billion in 2006.

29th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics